Summary by Moomoo AI
Sino Biopharmaceutical Limited ("the Company") has announced its interim results for the six months ended 30 June 2024. During the period, the Company's revenue reached RMB 15.87 billion, an increase of 11.1% compared to RMB 14.28 billion in the same period last year. The Company's main business covers the entire industry chain of research and development platform, intelligent production and sales system, and its products include various biological and chemical drugs, in which the Company has an advantageous position in the four major treatment areas of tumors, liver diseases, respiratory systems, and surgery / analgesia. During the period, the Company's R&D investment continued to increase, and multiple innovative products were approved for listing. The Company was listed on the Hong Kong Stock Exchange in 2000 and has been selected for several important indices for many years. The Company will continue to focus on innovation, promote international layout, and strive to improve the efficiency and quality of R&D in core treatment areas. The Company announced a mid-term dividend of HK$0.03 per ordinary share.
